Bellerophon Therapeutics Inc. shares skyrocketed in the extended session Thursday after the tiny biotech reported a mid-stage clinical study showed its drug Inopulse benefitted patients with high blood pressure in arteries that connect the lungs to the heart. Bellerophon shares jumped 72% to $6.40. The company said early study data showed Inopulse provided a sustained benefit in patients with Pulmonary Arterial Hypertension. Also, Bellerophon said the Food and Drug Administration declared that the company’s design and clinical endpoints for a planned late-stage clinical trial for the drug were acceptable.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News